Cyclacel Pharmaceuticals, Inc.

NasdaqCM:CYCC Stock Report

Market Cap: US$702.8k

Cyclacel Pharmaceuticals Valuation

Is CYCC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CYCC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CYCC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CYCC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CYCC?

Key metric: As CYCC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CYCC. This is calculated by dividing CYCC's market cap by their current revenue.
What is CYCC's PS Ratio?
PS Ratio9.2x
SalesUS$74.00k
Market CapUS$702.82k

Price to Sales Ratio vs Peers

How does CYCC's PS Ratio compare to its peers?

The above table shows the PS ratio for CYCC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.8x
NSTM NovelStem International
43.4xn/aUS$520.4k
SCPX Scorpius Holdings
0.2x50.1%US$2.1m
THER Theralink Technologies
1xn/aUS$615.1k
TRVN Trevena
2.7x-6.1%US$1.5m
CYCC Cyclacel Pharmaceuticals
9.2x82.9%US$702.8k

Price-To-Sales vs Peers: CYCC is good value based on its Price-To-Sales Ratio (9.2x) compared to the peer average (11.8x).

Price to Sales Ratio vs Industry

How does CYCC's PS Ratio compare vs other companies in the US Biotechs Industry?

128 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
4x2.4%US$112.40b
BIIB Biogen
2.4x1.3%US$23.01b
MRNA Moderna
3.3x6.8%US$15.82b
INCY Incyte
3.5x9.0%US$13.82b
CYCC 9.2xIndustry Avg. 9.4xNo. of Companies128PS01632486480+
128 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CYCC is good value based on its Price-To-Sales Ratio (9.2x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is CYCC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CYCC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.2x
Fair PS Ratio16.3x

Price-To-Sales vs Fair Ratio: CYCC is good value based on its Price-To-Sales Ratio (9.2x) compared to the estimated Fair Price-To-Sales Ratio (16.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

7D

6.8%

1Y

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

7D

6.1%

1Y

14.8%